After further analyzing the recently available clinical data set containing chemotherapeutic information (breast cancer TCGA, cBioPortal, Nature Communications 2016), we found that TNBC patients treated with chemotherapeutic drugs exhibited poor survival rate (66.7 vs 282.8 months, P=0.00071) and shorter disease-free survival time (P=0.00208) if tumor samples expressed higher levels of IL8, CXCR1, CXCR2 and the Wnt target genes than those expressed lower levels (Figure 4b). The gene discussed is CXCR2; the disease is breast carcinoma.